Both CDMOs and CMOs are now looking to make strategic investments to vastly expand the services they can offer clients. For example, the pharma industry is increasingly looking for, and the contract services sector is moving towards, providing a one-stop-shop for both APIs and finished forms in development and commercialisation. The major advantage for a pharma company is that being able to source both drug substance and product development from a single vendor will minimise the cost and complexity of the overall product, potentially reducing the time to market. From the CDMO perspective, being well equipped to help maximise the value of the complete drug package allows for more strategic partnerships with shared objectives and forward thinking development plans that take predicted volumes and manufacturing requirements into account from an early stage.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.
Subscribe now Already a subscriber? Sign in here.